Skip to main content

Table 1 Biochemical markers and characteristics (mean ± SD) of the male HIV-1 infected subjects with hypogonadism (group I); HIV-1 infected male eugonadal patients and healthy controls (significance between HIV-1 infected men of group I or II and controls * p < 0.05) (significance between hypogonadal and eugonadal patients # p < 0.05)

From: Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART)

Parameter

Group I

(n = 32)

Group II

(n = 48)

Group III

(n = 20)

Range

 

HIV-1

hypogonadism

HIV-1

eugonadism

Male, control

 

Weight [kg]

71.4 ± 4.2 *

74.7 ± 3.6

78.5 ± 4.7

 

Body mass index [kg/m2]

24.1 ± 2.2

24.9 ± 3.1

26.05 ± 5.5

 

Age [yr]

39.1 ± 7.2

35.2 ± 4.3

35.4 ± 4.1

 

Smoker [total]

10

30

5

 

Unemployed [total]

8

15

0

 

Heroin addict

4

0

0

 

Cotrim [total]

15

23

0

 

Tuberculostatica [total]

1

2

0

 

CD4 cell count [total]

153.5 ± 56.2 *#

235.5 ± 37.5 *

890.0 ± 69.1

610-970 [total]

Prolactin [mIU/ml]

31.1 ± 3.7

27.4 ± 2.05

30.8 ± 5.3

20-50 [mIU/ml]

FSH [mIU/ml]

2.15 ± 1.4 *#

4.2 ± 3.1

3.6 ± 2.6

2.2-19.6 [mIU/ml]

LH [mIU/ml]

1.9 ± 2.5 *#

3.2 ± 2.2

3.2 ± 1.4

2.5-99.5 [mIU/ml]

Testosterone total [ng/dl]

149.2 ± 62.5 *#

601.0 ± 73.2

534.4 ± 45.8

300-1000 [ng/dl]